OTLK · Outlook Therapeutics, Inc.

Operating results reflected the challenges of early-stage commercialization in Europe for LYTENAVA, our approved ophthalmic product, while cost management efforts provided some relief. Gross profit stood at -$21.9K for the quarter ended March 31, 2026. Cost of revenues consists primarily of inventory sold costs, including direct manufacturing, production, and packaging materials for LYTENAVA sales. Management notes that research and development expenses that would have been classified as cost of revenues were immaterial, underscoring the nascent stage of revenue generation from EU/UK launches.

Operating income totaled -$14.0M, widening 13.2% from -$12.4M in the prior-year quarter. This increase in loss was primarily due to higher Europe commercial expenses, partially offset by a decrease in stock-based compensation. The company expanded into Austria in 2026 and plans launches in other EU countries directly or via licensing partners, driving these commercial investments. Such expansion exposes the business to supply chain risks, including potential tariffs that could increase complexity and disrupt existing arrangements.

Cash flow from operating activities used -$22.8M, less than the -$27.6M in the prior year, benefiting from the noted cost reductions. However, persistent cash burn highlights liquidity pressures. Management commentary warns that market disruptions could hinder access to capital on favorable terms, negatively impacting strategy execution. Cost reduction plans carry execution risks, potentially accelerating liquidity needs and forcing operational curtailments if benefits are not realized on timeline. For the six months ended March 31, 2026, negative revenue stemmed from a returns reserve increase tied to lower-than-forecasted UK distributor sell-through, illustrating commercialization execution risks.